SYNAGIS (Palivizumab) for Respiratory Syncytial Virus (RSV)

Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The

Related Keywords

United Kingdom ,United States ,Germany ,Japan ,Dublin ,Ireland ,Italy ,France ,Spain , ,Clinical Development ,Market Insight ,Topics Covered ,Marketed Therapies ,Late Stage Emerging Therapies ,Research And Markets ,Synagis ,Vaccines ,